indinavir的遗传特点,齐多夫定、拉米夫定治疗感染艾滋病病毒的成人:一个试点研究。
文章的细节
-
引用
复制到剪贴板 -
安德森PL, J,兰Aquilante CL, Schuetz E,弗莱彻的简历
indinavir的遗传特点,齐多夫定、拉米夫定治疗感染艾滋病病毒的成人:一个试点研究。
J Acquir免疫Defic Syndr。2006年8月1;42 (4):441 - 9。
- PubMed ID
-
16791115 (在PubMed]
- 文摘
-
目的:这项研究的目的是调查indinavir之间的关系,lamivudine-triphosphate,和zidovudine-triphosphate CYP3A5多态性,药代学和药效学凋亡,MRP2 MRP4 BCRP, UGT1A1基因。研究设计:回顾性试点调查中33个受试者参与随机药理研究indinavir,拉米夫定,齐多夫定。受试者被定义为基因变异携带者。与多变量之间的关系进行了回归。为非裔美国人的种族Indinavir间隙调整;三磷酸腺苷对性;和艾滋病毒反应研究的手臂,药物暴露和基线hiv rna。结果:由基因决定CYP3A5明示了快44% indinavir口服间隙与nonexpressors (P = 0.002)。MRP2-24C / T变体航空公司快24% indinavir口服间隙(P = 0.05)。Lamivudine-triphosphate浓度升高20% MRP4 T4131G变体运营商(P = 0.004)。 A trend for elevated zidovudine-triphosphates was observed in MRP4 G3724A variant carriers (P = 0.06). The log10 changes in HIV-RNA from baseline to week 52 were -3.7 for MDR1 2677 TT, -3.2 for GT, and -2.2 for GG (P < 0.05). Bilirubin increases were 2-fold higher in UGT1A1 [TA]7/[TA]7 genotypes. No relationships were identified with BCRP. DISCUSSION: Novel relationships were identified among genetic variants in drug transporters and indinavir, lamivudine-triphosphate, and zidovudine-triphosphate concentrations. CYP3A5 expression was associated with faster indinavir oral clearance. These pilot data provide a scientific basis for more rational utilization of antiretroviral drugs.